BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: Set to grow at a double digit growth rate, compounded annually, the global microfluidics market will be a hotbed of growth opportunities for market players between 2017 and 2025.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The global life sciences software market is expected to expand at a healthy rate from 2021 to 2031.

The leading players in global surgical display market offer unique and capable solutions for their end users operating in the healthcare and medical industry.

The rise in geriatric population and their vulnerability to various diseases increases hospital visits for proper check-up.

Fact.MR, a market research and competitive intelligence provider: The global self-administered medication market is estimated at USD 87.5 Billion in 2022 and is forecast to surpass USD 200.5 Billion by 2032, growing at a CAGR of 8.6% from 2022 to 2032.

ClearMind Biomedical’s novel neurosurgical endoscope, the Axonpen System, has completed its First in Man clinical trial in Taiwan with outstanding results.

Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, announced a publication in Nature Communications demonstrating that the histone lysine methyltransferase enzyme Suv39h1 plays not only a key role in T cell persistence, but also in T cell activation and exhaustion.

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory follicular lymphoma who have received at least two prior systemic therapies.

BiomX Inc., a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announced that it is voluntarily delisting its shares of common stock from trading on the Tel Aviv Stock Exchange.

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.